1FG0.F Kyntra Bio, Inc.
- Market cap
- EUR 12.2M
- P/E
- -
- P/B
- 79.58x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1FG0.F undervalued?
Graham numberThe Graham number of Kyntra Bio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kyntra Bio, Inc. fundamental analysis
No fundamental analysis for Kyntra Bio, Inc. yet.
Kyntra Bio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical developme…
Full company profileKyntra Bio, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kyntra Bio, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 235M | 141M | 46.8M | 29.6M | 6.44M | 4.53M |
| Gross Profit | 222M | 120M | 42.8M | 14.1M | 5.88M | -3.69M |
| Operating Income | -289M | -301M | -310M | -131M | -45.3M | -62.7M |
| EBITDA | - | -283M | -305M | -142M | -48.8M | 3.30M |
| Net Income | -290M | -294M | -284M | -47.6M | 183M | -6.45M |
| EPS | -78 | -78 | -72 | -12 | 45 | -1.59 |
| Balance Sheet | ||||||
| Total Assets | 774M | 610M | 424M | 215M | 120M | 101M |
| Total Liabilities | 545M | 612M | 586M | 398M | 115M | 109M |
| Shareholders' Equity | 209M | -21.4M | -204M | -226M | -30.0M | -30.1M |
| Cash & Short-term Investments | 171M | 156M | 81.6M | 50.5M | 47.9M | 50.6M |
| Cash Flow | ||||||
| Operating Cash Flow | -82.2M | -146M | -315M | -138M | -4.77M | -35.8M |
| Capital Expenditure | 30.2M | 38.7M | 2.52M | 266K | 38.0K | 0.00 |
| Free Cash Flow | -112M | -185M | -318M | -138M | -4.81M | -35.8M |
| Ratios | ||||||
| ROE | -138.7% | - | - | - | - | - |
| ROA | -37.5% | -48.1% | -67.1% | -22.2% | 153.4% | -6.4% |
| Net Profit Margin | -123.3% | -208.7% | -607.3% | -160.6% | 2,848.6% | -142.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Kyntra Bio, Inc. dividends
Kyntra Bio, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:25 on Jun 17, 2025.
Who owns Kyntra Bio, Inc.
- Insiders 2.02%
- Institutions 24.63%
- Public & others 73.35%
- Shares outstanding 4.05M
- Free float 3.57M
Kyntra Bio, Inc. company profile
- Company name
- Kyntra Bio, Inc.
- Ticker
- 1FG0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 34
- Fiscal year end
- December
- Address
- 350 Bay Street, San Francisco, CA, United States, 94133
- Phone
- 415 978 1200
- Website
- kyntrabio.com
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Kyntra Bio, Inc. management
7- Mr. Thane WettigCEO & Director · born 1965
- Mr. David DeLuciaSenior VP & CFO · born 1989
- Mr. John AldenCorporate Secretary & General Counsel
- Ms. Michelle SimonettiHead of People and Culture & Executive Director
- Dr. Carrie Brownstein M.D.Chief Medical Officer · born 1970
- Ms. Gaia Vasiliver-ShamisDirector of IR & Communications - LifeSci Advisors
- Ms. Carol GaddumVice President of Product Development